{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:26:09Z","timestamp":1769088369938,"version":"3.49.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1124\/jpet.120.000123","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T04:45:21Z","timestamp":1595997921000},"page":"127-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Drug Discovery Strategies for SARS-CoV-2"],"prefix":"10.1016","volume":"375","author":[{"given":"Zeenat A.","family":"Shyr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirill","family":"Gorshkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine Z.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.120.000123_bib1","doi-asserted-by":"crossref","first-page":"e1973","DOI":"10.1002\/rmv.1973","article-title":"Autophagy: the multi-purpose bridge in viral infections and host cells","volume":"28","author":"Abdoli","year":"2018","journal-title":"Rev Med Virol"},{"key":"10.1124\/jpet.120.000123_bib2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"key":"10.1124\/jpet.120.000123_bib3","doi-asserted-by":"crossref","first-page":"104228","DOI":"10.1016\/j.micpath.2020.104228","article-title":"In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect","volume":"145","author":"Andreani","year":"2020","journal-title":"Microb Pathog"},{"key":"10.1124\/jpet.120.000123_bib4","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMe2005477","article-title":"Covid-19 - the search for effective therapy","volume":"382","author":"Baden","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.120.000123_bib5","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/phar.2398","article-title":"Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019","volume":"40","author":"Barlow","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1124\/jpet.120.000123_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 - preliminary report","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.120.000123_bib7","first-page":"213135","article-title":"Inhibition of RNA helicases of ssRNA(+) virus belonging to Flaviviridae, Coronaviridae and Picornaviridae families","volume":"2011","author":"Briguglio","year":"2011","journal-title":"Int J Med Chem"},{"key":"10.1124\/jpet.120.000123_bib8","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1124\/jpet.120.000123_bib9","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.120.000123_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cellsig.2017.04.001","article-title":"Niclosamide: beyond an antihelminthic drug","volume":"41","author":"Chen","year":"2018","journal-title":"Cell Signal"},{"key":"10.1124\/jpet.120.000123_bib11","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.4014\/jmb.1507.07078","article-title":"Identification of a novel small molecule inhibitor against SARS coronavirus helicase","volume":"25","author":"Cho","year":"2015","journal-title":"J Microbiol Biotechnol"},{"key":"10.1124\/jpet.120.000123_bib12","doi-asserted-by":"crossref","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1124\/jpet.120.000123_bib13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.coviro.2017.03.002","article-title":"Tackling influenza with broadly neutralizing antibodies","volume":"24","author":"Corti","year":"2017","journal-title":"Curr Opin Virol"},{"key":"10.1124\/jpet.120.000123_bib14","doi-asserted-by":"crossref","first-page":"104667","DOI":"10.1016\/j.antiviral.2019.104667","article-title":"A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity","volume":"173","author":"Cubitt","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1124\/jpet.120.000123_bib15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.virol.2009.09.023","article-title":"A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo","volume":"395","author":"Day","year":"2009","journal-title":"Virology"},{"key":"10.1124\/jpet.120.000123_bib16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.virol.2017.12.024","article-title":"An \u201cOld\u201d protein with a new story: coronavirus endoribonuclease is important for evading host antiviral defenses","volume":"517","author":"Deng","year":"2018","journal-title":"Virology"},{"key":"10.1124\/jpet.120.000123_bib17","doi-asserted-by":"crossref","first-page":"105938","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","volume":"55","author":"Devaux","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1124\/jpet.120.000123_bib18","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"de Wilde","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.120.000123_bib19","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"de Wit","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.120.000123_bib20","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa030747","article-title":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome","volume":"348","author":"Drosten","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.120.000123_bib21","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.120.000123_bib22","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.120.000123_bib23","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/art.1780371012","article-title":"The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis","volume":"37","author":"Felson","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.120.000123_bib24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad, Ser B, Phys Biol Sci"},{"key":"10.1124\/jpet.120.000123_bib25","first-page":"207","article-title":"[Preventive and therapeutic effects of recombinant IFN-alpha2b nasal spray on SARS-CoV infection in Macaca mulata]","volume":"19","author":"Gao","year":"2005","journal-title":"Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi"},{"key":"10.1124\/jpet.120.000123_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1124\/jpet.120.000123_bib27","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1128\/JVI.00128-13","article-title":"The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies","volume":"87","author":"Gierer","year":"2013","journal-title":"J Virol"},{"key":"10.1124\/jpet.120.000123_bib28","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1128\/JVI.02232-10","article-title":"Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response","volume":"85","author":"Glowacka","year":"2011","journal-title":"J Virol"},{"key":"10.1124\/jpet.120.000123_bib29","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.120.000123_bib30","doi-asserted-by":"crossref","first-page":"8094","DOI":"10.1073\/pnas.1921485117","article-title":"Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors","volume":"117","author":"Hackbart","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.120.000123_bib31","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41579-019-0233-2","article-title":"Therapeutic strategies to target the Ebola virus life cycle","volume":"17","author":"Hoenen","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1124\/jpet.120.000123_bib32","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1124\/jpet.120.000123_bib33","doi-asserted-by":"crossref","first-page":"e00754","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.120.000123_bib34","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1124\/jpet.120.000123_bib35","doi-asserted-by":"crossref","first-page":"e01815","DOI":"10.1128\/JVI.01815-18","article-title":"TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection","volume":"93","author":"Iwata-Yoshikawa","year":"2019","journal-title":"J Virol"},{"key":"10.1124\/jpet.120.000123_bib36","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.isci.2019.07.003","article-title":"The FDA-approved oral drug nitazoxanide amplifies host antiviral responses and inhibits Ebola virus","volume":"19","author":"Jasenosky","year":"2019","journal-title":"iScience"},{"key":"10.1124\/jpet.120.000123_bib37","doi-asserted-by":"crossref","first-page":"e00819","DOI":"10.1128\/AAC.00819-20","article-title":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs","volume":"64","author":"Jeon","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.120.000123_bib38","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1038\/emi.2014.88","article-title":"Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs","volume":"3","author":"Kouznetsova","year":"2014","journal-title":"Emerg Microbes Infect"},{"key":"10.1124\/jpet.120.000123_bib39","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med"},{"key":"10.1124\/jpet.120.000123_bib40","series-title":"Dynamics of Immune Activation in Viral Diseases","first-page":"9","article-title":"Antibody-dependent enhancement of viral infections","author":"Kulkarni","year":"2020"},{"key":"10.1124\/jpet.120.000123_bib41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.antiviral.2011.02.003","article-title":"Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB\/c mouse model by stinging nettle lectin, Urtica dioica agglutinin","volume":"90","author":"Kumaki","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1124\/jpet.120.000123_bib42","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1124\/jpet.120.000123_bib43","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID-19","volume":"10","author":"Li","year":"2020","journal-title":"J Pharm Anal"},{"key":"10.1124\/jpet.120.000123_bib44","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1124\/jpet.120.000123_bib45","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2174\/1568026619666190712204603","article-title":"Discovery and development of anti-HIV therapeutic agents: progress towards improved HIV medication","volume":"19","author":"Maeda","year":"2019","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/jpet.120.000123_bib46","doi-asserted-by":"crossref","first-page":"197989","DOI":"10.1016\/j.virusres.2020.197989","article-title":"Natural product-derived phytochemicals as potential agents against coronaviruses: a review","volume":"284","author":"Mani","year":"2020","journal-title":"Virus Res"},{"key":"10.1124\/jpet.120.000123_bib47","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1099\/vir.0.2008\/003962-0","article-title":"Interaction of severe acute respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting enzyme-2","volume":"89","author":"Mathewson","year":"2008","journal-title":"J Gen Virol"},{"key":"10.1124\/jpet.120.000123_bib48","doi-asserted-by":"crossref","first-page":"12658","DOI":"10.1128\/JVI.01542-10","article-title":"Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2","volume":"84","author":"Matsuyama","year":"2010","journal-title":"J Virol"},{"key":"10.1124\/jpet.120.000123_bib49","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1073\/pnas.2002589117","article-title":"Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells","volume":"117","author":"Matsuyama","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.120.000123_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2016.07.011","article-title":"Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin","volume":"133","author":"Millet","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1124\/jpet.120.000123_bib51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.antiviral.2017.03.007","article-title":"Antiviral lectins: selective inhibitors of viral entry","volume":"142","author":"Mitchell","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1124\/jpet.120.000123_bib52","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"key":"10.1124\/jpet.120.000123_bib53","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1074\/jbc.M411122200","article-title":"Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp","volume":"280","author":"Mori","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.120.000123_bib54","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cbic.202000047","article-title":"Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV","volume":"21","author":"Morse","year":"2020","journal-title":"ChemBioChem"},{"key":"10.1124\/jpet.120.000123_bib55","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.120.000123_bib56","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41564-019-0392-y","article-title":"Antibody responses to viral infections: a structural perspective across three different enveloped viruses","volume":"4","author":"Murin","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1124\/jpet.120.000123_bib57","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1107\/S1399004715003521","article-title":"Structures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity","volume":"71","author":"Needle","year":"2015","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1124\/jpet.120.000123_bib58","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1128\/JVI.02322-09","article-title":"Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae","volume":"84","author":"O\u2019Keefe","year":"2010","journal-title":"J Virol"},{"key":"10.1124\/jpet.120.000123_bib59","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat Commun"},{"key":"10.1124\/jpet.120.000123_bib60","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2011400","article-title":"Multiorgan and renal tropism of SARS-CoV-2","author":"Puelles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.120.000123_bib61","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.it.2020.02.007","article-title":"SARS coronavirus redux","volume":"41","author":"Qing","year":"2020","journal-title":"Trends Immunol"},{"key":"10.1124\/jpet.120.000123_bib62","doi-asserted-by":"crossref","first-page":"103670","DOI":"10.1016\/j.compbiomed.2020.103670","article-title":"Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus","volume":"119","author":"Robson","year":"2020","journal-title":"Comput Biol Med"},{"key":"10.1124\/jpet.120.000123_bib63","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3390\/cells9051267","article-title":"A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping","volume":"9","author":"Romano","year":"2020","journal-title":"Cells"},{"key":"10.1124\/jpet.120.000123_bib64","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jiph.2016.04.001","article-title":"Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus","volume":"9","author":"Rossignol","year":"2016","journal-title":"J Infect Public Health"},{"key":"10.1124\/jpet.120.000123_bib65","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41590-018-0233-9","article-title":"Antibody-mediated protection against Ebola virus","volume":"19","author":"Saphire","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1124\/jpet.120.000123_bib66","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today\u2019s diseases?","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1124\/jpet.120.000123_bib67","first-page":"25","article-title":"Ciclesonide: a safe and effective inhaled corticosteroid for the treatment of asthma","volume":"2","author":"Schaffner","year":"2009","journal-title":"J Asthma Allergy"},{"key":"10.1124\/jpet.120.000123_bib68","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41231-019-0050-7","article-title":"Lost in translation: the valley of death across preclinical and clinical divide \u2013 identification of problems and overcoming obstacles","volume":"4","author":"Seyhan","year":"2019","journal-title":"Transl Med Commun"},{"key":"10.1124\/jpet.120.000123_bib69","first-page":"10","article-title":"Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)","volume":"38","author":"Shanmugaraj","year":"2020","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1124\/jpet.120.000123_bib70","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1124\/jpet.120.000123_bib71","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1124\/jpet.120.000123_bib72","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/JVI.02062-10","article-title":"A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry","volume":"85","author":"Shulla","year":"2011","journal-title":"J Virol"},{"key":"10.1124\/jpet.120.000123_bib73","doi-asserted-by":"crossref","first-page":"104759","DOI":"10.1016\/j.antiviral.2020.104759","article-title":"A potential role for integrins in host cell entry by SARS-CoV-2","volume":"177","author":"Sigrist","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1124\/jpet.120.000123_bib74","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1124\/jpet.120.000123_bib75","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.antiviral.2016.11.017","article-title":"Synergistic drug combination effectively blocks Ebola virus infection","volume":"137","author":"Sun","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1124\/jpet.120.000123_bib76","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","article-title":"Drug combination therapy increases successful drug repositioning","volume":"21","author":"Sun","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1124\/jpet.120.000123_bib77","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1124\/jpet.120.000123_bib78","doi-asserted-by":"crossref","first-page":"104792","DOI":"10.1016\/j.antiviral.2020.104792","article-title":"Coronavirus membrane fusion mechanism offers a potential target for antiviral development","volume":"178","author":"Tang","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1124\/jpet.120.000123_bib79","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1124\/jpet.120.000123_bib80","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jviromet.2009.10.020","article-title":"An enzymatic virus-like particle assay for sensitive detection of virus entry","volume":"163","author":"Tscherne","year":"2010","journal-title":"J Virol Methods"},{"key":"10.1124\/jpet.120.000123_bib81","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.3390\/ijms21072657","article-title":"A review of SARS-CoV-2 and the ongoing clinical trials","volume":"21","author":"Tu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.120.000123_bib82","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1124\/jpet.120.000123_bib83","doi-asserted-by":"crossref","first-page":"e00127","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"10.1124\/jpet.120.000123_bib84","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/cr.2008.15","article-title":"SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res"},{"key":"10.1124\/jpet.120.000123_bib85","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1124\/jpet.120.000123_bib86","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41421-020-0169-8","article-title":"The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro","volume":"6","author":"Wang","year":"2020","journal-title":"Cell Discov"},{"key":"10.1124\/jpet.120.000123_bib87","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1128\/JVI.00948-15","article-title":"Coronavirus nsp10\/nsp16 methyltransferase can be targeted by nsp10-derived peptide in vitro and in vivo to reduce replication and pathogenesis","volume":"89","author":"Wang","year":"2015","journal-title":"J Virol"},{"key":"10.1124\/jpet.120.000123_bib88","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1124\/jpet.120.000123_bib89","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1124\/jpet.120.000123_bib90","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1124\/jpet.120.000123_bib91","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res"},{"key":"10.1124\/jpet.120.000123_bib92","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/acsinfecdis.0c00052","article-title":"Broad spectrum antiviral agent niclosamide and its therapeutic potential","volume":"6","author":"Xu","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1124\/jpet.120.000123_bib93","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11427-020-1637-5","article-title":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission","volume":"63","author":"Xu","year":"2020","journal-title":"Sci China Life Sci"},{"key":"10.1124\/jpet.120.000123_bib94","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.7150\/ijbs.45498","article-title":"Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19","volume":"16","author":"Yang","year":"2020","journal-title":"Int J Biol Sci"},{"key":"10.1124\/jpet.120.000123_bib95","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41421-018-0034-1","article-title":"Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry","volume":"4","author":"Yang","year":"2018","journal-title":"Cell Discov"},{"key":"10.1124\/jpet.120.000123_bib96","doi-asserted-by":"crossref","first-page":"100618","DOI":"10.1016\/j.cpcardiol.2020.100618","article-title":"COVID-19 and multiorgan response","volume":"45","author":"Zaim","year":"2020","journal-title":"Curr Probl Cardiol"},{"key":"10.1124\/jpet.120.000123_bib97","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.120.000123_bib98","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bph.13895","article-title":"Drug repurposing screens and synergistic drug-combinations for infectious diseases","volume":"175","author":"Zheng","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.000123_bib99","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1124\/jpet.120.000123_bib100","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1124\/jpet.120.000123_bib101","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses - drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat Rev Drug Discov"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524270038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524270038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.120.000123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:27:12Z","timestamp":1739964432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524270038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0022356524270038"],"URL":"https:\/\/doi.org\/10.1124\/jpet.120.000123","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug Discovery Strategies for SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.120.000123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"U.S. Government work not protected by U.S. copyright","name":"copyright","label":"Copyright"}]}}